Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.

about

Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q38438248

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Prognostic, predictive and pot ...... ion-resistant prostate cancer.

@en

type

Item

label

Prognostic, predictive and pot ...... ion-resistant prostate cancer.

@en

prefLabel

Prognostic, predictive and pot ...... ion-resistant prostate cancer.

@en

P1476

Prognostic, predictive and pot ...... ion-resistant prostate cancer.

@en

P2093

Atiqullah Aziz

http://www.w3.org/2001/XMLSchema#string

Carsten Kempkensteffen

http://www.w3.org/2001/XMLSchema#string

Felix K-H Chun

http://www.w3.org/2001/XMLSchema#string

Matthias May

http://www.w3.org/2001/XMLSchema#string

Maximilian Burger

http://www.w3.org/2001/XMLSchema#string

Steffen Lebentrau

http://www.w3.org/2001/XMLSchema#string

P2860

Improved endpoints for cancer immunotherapy trials

Understanding the Warburg effect: the metabolic requirements of cell proliferation

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

P304

649-666

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2015.1038247

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sabine Brookman-May

P577

2015-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25905802

http://www.w3.org/2001/XMLSchema#string